{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/","result":{"pageContext":{"chapter":{"id":"4c571c2d-718a-5351-ba2b-f3c8d69a15c4","slug":"progestogen-only-implant","fullItemName":"Scenario: Progestogen-only implant","depth":2,"htmlHeader":"<!-- begin field 1c099109-43bb-433f-96db-b2f410fe49c7 --><h2>Scenario: Progestogen-only implant</h2><!-- end field 1c099109-43bb-433f-96db-b2f410fe49c7 -->","summary":"Covers the use of the progestogen-only implant, including the available products; when to start it; the efficacy; the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception.","htmlStringContent":"<!-- begin item 5582cbdb-bafc-48ca-9236-afa47610ebb6 --><!-- begin field 34db36b8-1eda-45b2-aafb-acbc015798ce --><p>From age 13 years to 60 years (Female).</p><!-- end field 34db36b8-1eda-45b2-aafb-acbc015798ce --><!-- end item 5582cbdb-bafc-48ca-9236-afa47610ebb6 -->","topic":{"id":"9ff99c6b-985a-5146-8ef5-665fc2b551bb","topicId":"832bfe6c-0c1e-4dca-89eb-7e914cf17833","topicName":"Contraception - progestogen-only methods","slug":"contraception-progestogen-only-methods","lastRevised":"Last revised in November 2019","chapters":[{"id":"e97a1889-5b3c-51c7-abca-435669821908","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9d1ba26b-0889-5782-a5dd-876d8d8965c8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e40c82f2-3cbd-56c2-b06f-b2d3bfae8a34","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3d3ddcb9-bbef-5443-9762-08bf7c296da4","slug":"changes","fullItemName":"Changes"},{"id":"5c8ed192-6ffb-5084-a621-3d1b14ea264d","slug":"update","fullItemName":"Update"}]},{"id":"c2b04259-e45f-54ea-ba94-5bc43975229b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c2cce341-0179-531a-bea7-9b8f9120b8c0","slug":"goals","fullItemName":"Goals"},{"id":"8aa31475-0c4c-5b7a-bbb7-82a288b1541c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"59f5527f-5091-5084-ab85-34cd87ab3424","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"14b43b64-8b02-5470-a6a1-41982cbed802","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1cd2c043-e2cd-5c97-9a82-32c5baf9f590","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71e31498-8434-55e9-9802-459d2ed956f5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"62d7d86a-7652-51fb-972e-f8113766a58c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ba99afb9-717a-59e6-b0af-a6fe316f6e0b","slug":"where-to-get-progestogen-only-contraception","fullItemName":"Where to get progestogen-only contraception"}]},{"id":"74f87f5c-2983-599c-9881-ad5d663100c0","fullItemName":"Management","slug":"management","subChapters":[{"id":"28c180bd-05b7-5bf7-8601-f61802a3f2b0","slug":"progestogen-only-pill","fullItemName":"Scenario: Progestogen-only pill"},{"id":"4c571c2d-718a-5351-ba2b-f3c8d69a15c4","slug":"progestogen-only-implant","fullItemName":"Scenario: Progestogen-only implant"},{"id":"a3632aab-62ce-5263-b365-24e12194e389","slug":"progestogen-only-injectables","fullItemName":"Scenario: Progestogen-only injectables"}]},{"id":"b040c0e0-cf32-51f5-8b09-18bca20a90c8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0b3c54f3-29e8-5d1b-af69-397a9b27760f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"654d1af0-9c4c-5d0a-90e6-d8cd8063b1c6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b1383200-8981-5368-ba45-a0d6bbbe92a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"05903434-c83e-5971-964b-85a3d8d7e8b3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3f865d6-8f60-5c7a-b522-6e18d274c84c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"39d2eca9-efb9-5f08-b73b-15fb2a3d4896","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d93103c6-16a2-5c1d-92ce-7a991173c791","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"74f87f5c-2983-599c-9881-ad5d663100c0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e4f06655-d643-5860-9386-67a662bf0707","slug":"starting-a-progestogen-only-implant","fullItemName":"Starting a progestogen-only implant","depth":3,"htmlHeader":"<!-- begin field 321a3fc3-ae81-4102-bf03-30fe20b44f19 --><h3>Starting a progestogen-only implant</h3><!-- end field 321a3fc3-ae81-4102-bf03-30fe20b44f19 -->","summary":null,"htmlStringContent":"<!-- begin item c68436da-a8ac-4698-8546-9f5529d0ef35 --><!-- end item c68436da-a8ac-4698-8546-9f5529d0ef35 -->","subChapters":[{"id":"f31b6054-e20d-5dee-b959-25395424e573","slug":"assessment","fullItemName":"Assessment","depth":4,"htmlHeader":"<!-- begin field 97e22bef-00e8-4170-a684-a7a700e6162a --><h4>How should I assess a woman before providing her with a progestogen-only implant?</h4><!-- end field 97e22bef-00e8-4170-a684-a7a700e6162a -->","summary":null,"htmlStringContent":"<!-- begin item c3414433-3b9f-45fe-912f-a7a700e612b6 --><!-- begin field d422c1b8-9c16-485b-b4d4-a7a700e6162a --><ul><li>For information on assessing a woman who is considering starting a progestogen-only implant, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/management/assessment-for-specific-contraceptive-methods/#progestogen-only-implant\">Progestogen-only implant</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul><!-- end field d422c1b8-9c16-485b-b4d4-a7a700e6162a --><!-- end item c3414433-3b9f-45fe-912f-a7a700e612b6 -->","subChapters":[]},{"id":"cc71e97c-b92f-5e5b-90c3-239b97eed47f","slug":"when-to-start","fullItemName":"When to start","depth":4,"htmlHeader":"<!-- begin field 5c6437c0-8931-482b-8c8f-145a5c3a71c8 --><h4>When can the progestogen-only implant be inserted?</h4><!-- end field 5c6437c0-8931-482b-8c8f-145a5c3a71c8 -->","summary":null,"htmlStringContent":"<!-- begin item 361075d0-895e-47b9-ad54-84059bc3a6ca --><!-- begin field f3df91e9-ac61-4703-9b4b-b4e997d79632 --><p>Specific advice for women who are amenorrhoeic, postpartum and breastfeeding, postpartum and not breastfeeding, post-termination of pregnancy or post-miscarriage is summarized in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#when-to-start-amenorrhoea\">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</a>. </p><ul><li><strong><strong>The progestogen-only implant  (Nexplanon®) must only be inserted by healthcare professionals who have been appropriately trained and accredited.</strong></strong></li><li><strong>If the woman is not currently using a regular method of contraception:</strong><ul><li>Ideally, insert the progestogen-only implant up to, and including day 5 of the menstrual cycle. <ul><li>No additional contraception is required.</li></ul></li><li>If this is not possible, insert the progestogen-only implant at any other time in the menstrual cycle provided it is reasonably certain that the women is not pregnant and that there is no risk of conception.<ul><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong> If the woman is starting the progestogen-only implant after oral emergency hormonal contraception:</strong><ul><li>For levonorgestrel, insert the implant immediately and advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li><li>For ulipristal acetate, insert the implant 5 days after taking ulipristal acetate and abstain from sex or use a barrier method of contraception (such as condoms) during this time and for the first 7 days after the implant has been inserted.</li><li>Advise the woman to have a pregnancy test no sooner than 3 weeks after unprotected sexual intercourse (UPSI).</li></ul></li><li><strong>If the woman is replacing an old progestogen-only implant with a new one:</strong><ul><li>If replacement is at, or within the licensed duration of 3 years, remove the old implant and immediately insert a new implant.<ul><li>No additional contraceptive cover is required.</li></ul></li><li>If replacement is beyond the licensed duration of 3 years, remove the old implant and immediately insert a new implant provided it is reasonably certain that the woman is not pregnant and there has been no risk of conception.<ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong>If the woman is changing from a combined hormonal contraceptive (CHC):</strong><ul><li>Insert the progestogen-only implant on day 1 of the hormone-free interval. <ul><li>No additional contraception is required.</li></ul></li><li>If the implant is inserted on week 1 of normal CHC use: <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li><li>If UPSI has occurred after day 3 of the hormone-free interval, advise restarting the CHC method for at least 7 days.</li></ul></li><li>If the implant is inserted on weeks 2–3 of normal CHC use:<ul><li>No additional contraceptive cover is required if the CHC method has been used consistently and correctly for the previous 7 days. </li></ul></li></ul></li><li><strong>If the woman is changing from the progestogen-only pill (POP) or </strong><strong>levonorgestrel intrauterine system (LNG-IUS):</strong><ul><li>Insert the implant at any time in the menstrual cycle.</li><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days, regardless of when in the menstrual cycle the implant is inserted. </li></ul></li><li><strong>If the woman is changing from an injectable progestogen-only contra</strong><strong>ceptive:</strong><ul><li>Insert the progestogen-only implant when the repeat injection is due, or up to 14 weeks after the last injection was given.<ul><li>No additional contraception is required.</li></ul></li><li>If the implant is inserted more than 14 weeks after the last injection:<ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days. </li><li>Emergency contraception will be required if UPSI occurs during this time.</li></ul></li></ul></li><li><strong>If the woman is changing from a barrier method of contraception (such as condoms), or the </strong><strong>copper intrauterine device (Cu-IUD):</strong><ul><li>Insert the progestogen-only implant on day 1–5 of the menstrual cycle.<ul><li>No additional contraception is required.</li></ul></li><li>If the progestogen-only implant is inserted at any other time in the menstrual cycle:<ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li><li>The Cu-IUD should be retained for 7 days if UPSI occurred in the 7 days before the implant was inserted.</li></ul></li></ul></li></ul><!-- end field f3df91e9-ac61-4703-9b4b-b4e997d79632 --><!-- end item 361075d0-895e-47b9-ad54-84059bc3a6ca -->","subChapters":[]},{"id":"a6b6de1f-5465-55b1-b347-a9093e78aba2","slug":"types-of-implant","fullItemName":"Types of implant","depth":4,"htmlHeader":"<!-- begin field 4839bce4-10a1-42ec-a605-251e09c7a65f --><h4>What progestogen-only implants are available?</h4><!-- end field 4839bce4-10a1-42ec-a605-251e09c7a65f -->","summary":null,"htmlStringContent":"<!-- begin item 78816381-ff85-47a7-bee5-0b7a6815c141 --><!-- begin field cd839195-bb78-46ef-951a-68f7f202d24d --><ul><li>Nexplanon® is currently the only progestogen-only implant licensed for use in the UK. <ul><li>It contains 68 mg of etonogestrel and comes in a preloaded applicator to reduce errors during insertion.</li><li>It is inserted under the skin (subdermally) in the inner part of the upper arm by healthcare professionals who have completed the appropriate training.</li><li>Designed to provide contraceptive cover for 3 years, it is radio-opaque and can be located by X-ray.</li></ul></li></ul><!-- end field cd839195-bb78-46ef-951a-68f7f202d24d --><!-- end item 78816381-ff85-47a7-bee5-0b7a6815c141 -->","subChapters":[]},{"id":"6cff5ad5-8d22-50f5-bf37-4cfc17c38d9d","slug":"mechanism-of-action","fullItemName":"Mechanism of action","depth":4,"htmlHeader":"<!-- begin field 1acf5b77-cb28-4ea9-bd1c-809e1343bdf6 --><h4>How do progestogen-only implants work?</h4><!-- end field 1acf5b77-cb28-4ea9-bd1c-809e1343bdf6 -->","summary":null,"htmlStringContent":"<!-- begin item 71745685-7503-4293-8ac9-46c279197e94 --><!-- begin field 3212af7b-d2f2-416d-a02f-9d19a9022f82 --><ul><li>The progestogen-only implant, Nexplanon®, prevents pregnancy by inhibiting ovulation. It also causes changes in cervical mucus that inhibit sperm.</li><li>Serum etonogestrel concentrations rise rapidly after insertion of the implant and ovulation is likely to be inhibited within 24 hours.</li></ul><!-- end field 3212af7b-d2f2-416d-a02f-9d19a9022f82 --><!-- end item 71745685-7503-4293-8ac9-46c279197e94 -->","subChapters":[]},{"id":"9cd138f0-e6e8-5896-8272-f5ad1f833bf1","slug":"when-to-start-amenorrhoea","fullItemName":"When to start - Amenorrhoea","depth":4,"htmlHeader":"<!-- begin field c3d448b9-6c10-4164-bff0-a6ce0097ac12 --><h4>Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</h4><!-- end field c3d448b9-6c10-4164-bff0-a6ce0097ac12 -->","summary":null,"htmlStringContent":"<!-- begin item cf68f45c-856c-4454-aa1a-a6ce0097aa71 --><!-- begin field 153d655e-8712-44a4-8ca6-a6ce0097ac12 --><ul><li><strong>If the woman is amenorrhoeic:</strong><ul><li>Insert the progestogen-only implant at any time if is reasonably certain the woman is not pregnant. <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li></ul><ul><li><strong>If the woman is postpartum (whether breastfeeding or not):</strong><ul><li>Insert the progestogen-only implant on or before day 21 postpartum. <ul><li>No additional contraception is required.</li></ul></li><li>If the implant is inserted after day 21 postpartum, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days, unless menstruation has started and the implant is inserted on days 1-5.</li></ul></li></ul><ul><li><strong>If the woman has had a miscarriage or termination of pregnancy:</strong><ul><li>If gestation is less than 24 weeks, ideally insert the implant immediately after a miscarriage, surgical termination, or the first part of a medical termination.<ul><li>If the progestogen-only implant is inserted within 5 days of miscarriage or termination, no additional contraception is required.</li><li>If the implant is inserted more than 5 days after miscarriage or abortion, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li><li>If gestation is 24 weeks or more, treat as for a woman who is postpartum.</li></ul></li></ul><!-- end field 153d655e-8712-44a4-8ca6-a6ce0097ac12 --><!-- end item cf68f45c-856c-4454-aa1a-a6ce0097aa71 -->","subChapters":[]},{"id":"828ca0b3-94c3-535e-88d7-d1e4d957b053","slug":"basis-for-recommendation-104","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 02fef75b-7f9d-4e55-86f5-a6ce0096ba9a --><h4>Basis for recommendation</h4><!-- end field 02fef75b-7f9d-4e55-86f5-a6ce0096ba9a -->","summary":null,"htmlStringContent":"<!-- begin item 1043b114-6fce-46c5-a126-a6ce0096b8b5 --><!-- begin field 0377bb89-13d4-4c9e-b712-a6ce0096ba9a --><h5>Types of implant</h5><ul><li>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only implants </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>], the Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>] and information in the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">BNF 71, 2016</a>].</li></ul><h5>Mechanism of action</h5><ul><li>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>], the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>] and information in the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">BNF 71, 2016</a>].</li></ul><h5>When to start</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>], <em>Contraception after pregnancy </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2017b</a>], and the <em>UK Medical Eligibility Criteria</em> <em>for contraceptive use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2016</a>], a statement from the FSRH clinical effectiveness unit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2015b</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</li></ul><!-- end field 0377bb89-13d4-4c9e-b712-a6ce0096ba9a --><!-- end item 1043b114-6fce-46c5-a126-a6ce0096b8b5 -->","subChapters":[]}]},{"id":"b27634c8-b007-59d8-abd1-b5da165d4853","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field ad8289a5-e877-40cd-92b9-25dd4fab82bc --><h3>What information and advice should I give a woman who is considering using a progestogen-only implant?</h3><!-- end field ad8289a5-e877-40cd-92b9-25dd4fab82bc -->","summary":null,"htmlStringContent":"<!-- begin item ac2504e5-44f1-437d-a082-543baf5fbd55 --><!-- begin field 78631ced-9a0d-4472-97ee-89c435b87d3b --><ul><li><strong>Discuss:</strong><ul><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#mechanism-of-action\">mechanism of action</a> of the progestogen-only implant.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#advantages-disadvantages\">advantages, disadvantages, and risks</a> of the progestogen-only implant.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#efficacy\">efficacy</a> of the progestogen-only implant.</li><li>What happens when the progestogen-only implant is removed.<ul><li>Advise the woman that normal fertility should return as soon as the progestogen-only implant is removed.</li></ul></li></ul></li><li><strong>Give advice on:</strong><ul><li>The possible <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#risks-adverse-effects\">adverse effects</a> (such as <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#risks-adverse-effects\">menstrual irregularities</a>) which may occur with the progestogen-only implant.</li><li>The possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#drug-interactions\">drug interactions</a>.<ul><li>Advise the woman to check with a healthcare professional before starting any new drug treatment (including herbal remedies).</li></ul></li></ul></li><li><strong>Provide written information on the progestogen-only implant.</strong><ul><li>The <a href=\"http://www.fpa.org.uk/\" data-hyperlink-id=\"9cb9b279-95af-4508-b073-a93100b7076a\">Family Planning Association</a> provides a useful <a href=\"http://www.fpa.org.uk/sites/default/files/contraceptive-implant-your-guide.pdf\" data-hyperlink-id=\"05337a99-322f-4c77-a5be-a93100b708e1\">leaflet</a> with information for users of the progestogen-only implant. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>]</p><!-- end field 78631ced-9a0d-4472-97ee-89c435b87d3b --><!-- end item ac2504e5-44f1-437d-a082-543baf5fbd55 -->","subChapters":[{"id":"0d7f4a90-dcc1-51ac-976a-7a605083c530","slug":"pregnancy","fullItemName":"Pregnancy","depth":4,"htmlHeader":"<!-- begin field 5397a810-6302-48c1-83f5-a7a700ea60e6 --><h4>How should I manage a woman who becomes pregnant whilst using the progestogen-only implant?</h4><!-- end field 5397a810-6302-48c1-83f5-a7a700ea60e6 -->","summary":null,"htmlStringContent":"<!-- begin item 906ac198-5113-48f3-9598-a7a700ea5d88 --><!-- begin field 51841f9e-953b-4583-946a-a7a700ea60e6 --><ul><li>If a woman is found to be pregnant whilst using the progestogen-only implant:<ul><li>Remove the implant.</li><li>Inform her that there is no evidence of harm to the baby or the mother if pregnancy occurs while using the progestogen-only implant.</li><li>Be alert to the possibility of an ectopic pregnancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/ectopic-pregnancy/\">Ectopic pregnancy</a> for more information.</li></ul></li></ul><!-- end field 51841f9e-953b-4583-946a-a7a700ea60e6 --><!-- end item 906ac198-5113-48f3-9598-a7a700ea5d88 -->","subChapters":[]},{"id":"6e69b66b-73e5-5bdc-a6da-c9bdb2ec6843","slug":"basis-for-recommendation-944","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 13c97c86-7018-4ffd-a45e-a6ce0099f6c1 --><h4>Basis for recommendation</h4><!-- end field 13c97c86-7018-4ffd-a45e-a6ce0099f6c1 -->","summary":null,"htmlStringContent":"<!-- begin item 94484488-9b51-4c09-bf8f-a6ce0099f51a --><!-- begin field 4d1ed5c0-24a7-4f3f-b923-a6ce0099f6c1 --><h5>Information and advice</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>].</li></ul><h5>Pregnancy</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>] and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</li></ul><!-- end field 4d1ed5c0-24a7-4f3f-b923-a6ce0099f6c1 --><!-- end item 94484488-9b51-4c09-bf8f-a6ce0099f51a -->","subChapters":[]}]},{"id":"92d5297f-4682-59c2-905d-93a01352b562","slug":"advantages-disadvantages","fullItemName":"Advantages and disadvantages","depth":3,"htmlHeader":"<!-- begin field 029b00c3-a97e-46cc-a376-f954b81fcc59 --><h3>What are the advantages and disadvantages of the progestogen-only implant?</h3><!-- end field 029b00c3-a97e-46cc-a376-f954b81fcc59 -->","summary":null,"htmlStringContent":"<!-- begin item 2678c603-49c0-46b2-afa8-6f0945a59514 --><!-- begin field 2ac804e4-c615-4ab9-8727-9f26a3761a8f --><div><strong>Advantages</strong></div><ul><li>The implant is very effective.</li><li>Users do not have to think about contraception for 3 years.</li><li>Sexual intercourse need not be interrupted to use the implant.</li><li>It can be used when breastfeeding.</li><li>Normal fertility returns as soon as the implant is removed.</li><li>It can be used in women for whom combined hormonal contraceptives are not recommended.</li><li>It may help alleviate dysmenorrhoea.</li><li>It may reduce the risk of endometrial cancer.</li><li>It is not associated with many serious adverse effects. <ul><li>There is little or no increased risk of venous thromboembolism, stoke, or myocardial infarction.  </li><li>It does not significantly adversely affect bone mineral density.</li></ul></li><li>It is effective in women of all weights.<ul><li>However, the manufacturers of Nexplanon® advises earlier replacement of the implant in 'heavier women', but do not provide guidance on the body mass index (BMI) above which the implant should be replaced earlier.</li></ul></li></ul><h4>Disadvantages</h4><ul><li>About 50% of women will experience changes in menstrual bleeding, and bleeding patterns are likely to remain irregular.</li><li>Contraceptive efficacy is likely to be reduced in women using liver enzyme-inducing drugs.</li><li>An implant does not protect against sexually transmitted infections (STIs).</li></ul><!-- end field 2ac804e4-c615-4ab9-8727-9f26a3761a8f --><!-- end item 2678c603-49c0-46b2-afa8-6f0945a59514 -->","subChapters":[{"id":"db43ae7a-5d0a-5f1f-831e-edbd8ab24976","slug":"basis-for-recommendation-118","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 102fbeb1-9662-4e61-bb91-bce11077357c --><h4>Basis for recommendation</h4><!-- end field 102fbeb1-9662-4e61-bb91-bce11077357c -->","summary":null,"htmlStringContent":"<!-- begin item 118db93c-e954-43e7-92ea-aca7b600133a --><!-- begin field c035d982-df79-4ec9-b558-b707cb56255b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>] and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</p><h5>Progestogen-only implant and replacement in 'heavier' women</h5><ul><li>The manufacturer of Nexplanon® suggests that healthcare professionals can consider replacing the implant earlier for 'heavier' women, however it does not clarify a weight above which this should be done [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>]. </li><li>The FSRH suggests that 70 kg might be an arbitary indicator for being 'heavier' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>].</li><li>However, no increased risk of pregnancy has been demonstrated in women weighing up to 149 kg, but because of the inverse relationship between weight and serum etonogestrel levels, a reduction in the duration of contraceptive efficacy cannot be completely excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>].</li></ul><!-- end field c035d982-df79-4ec9-b558-b707cb56255b --><!-- end item 118db93c-e954-43e7-92ea-aca7b600133a -->","subChapters":[]}]},{"id":"b3a07279-f58f-5f2f-aeb5-b857a5c26d20","slug":"risks-adverse-effects","fullItemName":"Risks and adverse effects","depth":3,"htmlHeader":"<!-- begin field 826686ab-fd0e-4ee1-a1f5-16b3b3e6d43c --><h3>What are the possible risks and adverse effects of the progestogen-only implant?</h3><!-- end field 826686ab-fd0e-4ee1-a1f5-16b3b3e6d43c -->","summary":null,"htmlStringContent":"<!-- begin item 566619c7-b044-4ed7-aa73-2b3bda496eed --><!-- begin field 25c59e27-7eab-4dbf-8706-935fe0d780ff --><ul><li><strong>Menstrual irregularities </strong>— see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#risks-adverse-effects\">Unscheduled bleeding</a> for more information.</li><li><strong>Acne </strong>— acne may occur or worsen (or improve) in some women.<ul><li>If acne occurs or worsens, consider prescribing suitable acne treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/acne-vulgaris/\">Acne vulgaris</a>.</li></ul></li><li><strong>Effect on bone mineral density </strong>— advise that there is no evidence of a clinically significant effect on bone mineral density with use of the progestogen-only implant.</li><li><strong>Complications of insertion and removal</strong> — Fitting and removing the implant requires a minor surgical procedure and may cause some pain, bruising, itching, or irritation.<ul><li>The surgical procedure can rarely (less than 1 in 100 women) cause problems such as an abscess, scarring, and migration or expulsion of the implant.</li><li>There have been reports of Nexplanon® breaking or bending in situ which may lead to a slightly increased rate of etonogestrel release.</li><li>There have been reports of Nexplanon® being found in the vasculature (including the pulmonary artery) and chest wall.</li></ul></li><li><strong>Increased cancer risk </strong>— there is a possible increased risk of breast cancer. However, this risk is very small compared with the overall risk of developing breast cancer, and gradually disappears within 10 years after stopping the progestogen-only implant, after which the risk of developing breast cancer is the same as for women that have never used hormonal contraceptives. For more information about the risks, which are the same as for progestogen-only pills, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#risks-adverse-effects\">Risks and adverse effects</a> in the <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/\">Scenario: Progestogen-only pill</a>.</li><li><strong>Venous thromboembolism (VTE)</strong><ul><li>Advise that there is little or no increase in risk of VTE associated with the use of progestogen-only implants.</li></ul></li><li><strong>There is no evidence that the progestogen-only implant causes:</strong><ul><li>Weight changes.</li><li>Headache.</li><li>Depression and mood changes.</li><li>Loss of libido.</li></ul></li></ul><!-- end field 25c59e27-7eab-4dbf-8706-935fe0d780ff --><!-- end item 566619c7-b044-4ed7-aa73-2b3bda496eed -->","subChapters":[{"id":"a10b9a75-0830-5ea7-a7b0-59559eb7f431","slug":"basis-for-recommendation-0f8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 044458cd-973d-4900-8b2a-5b9b5df048ff --><h4>Basis for recommendation</h4><!-- end field 044458cd-973d-4900-8b2a-5b9b5df048ff -->","summary":null,"htmlStringContent":"<!-- begin item 0f81649c-0d44-49cd-9809-d552f95a8ddf --><!-- begin field 833822ba-e428-4f78-9f36-60e2c521366b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>] and <em>Problematic bleeding with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2015c</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">NICE, 2015</a>], a Medicine and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">MHRA, 2016</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</p><!-- end field 833822ba-e428-4f78-9f36-60e2c521366b --><!-- end item 0f81649c-0d44-49cd-9809-d552f95a8ddf -->","subChapters":[]},{"id":"e3834c61-4659-53ab-8e6d-6d0c8eb3bcd4","slug":"unscheduled-bleeding","fullItemName":"Unscheduled bleeding","depth":4,"htmlHeader":"<!-- begin field 55c0c761-70da-4908-a765-a6ce009b33a8 --><h4>How should I manage unscheduled bleeding in a woman using a progestogen-only implant?</h4><!-- end field 55c0c761-70da-4908-a765-a6ce009b33a8 -->","summary":null,"htmlStringContent":"<!-- begin item 55c12934-eda3-4778-a6f7-a6ce009b31ea --><!-- begin field d7a5c6fa-35c0-4a69-a2ac-a6ce009b33a8 --><ul><li><strong>Exclude and/or manage situations which could result in unscheduled bleeding, such as:</strong><ul><li>Sexually transmitted infections (STIs) — as a minimum, test for <em>Chlamydia trachomatis</em>. The risk of STIs is increased if the woman is under 25 years, has a new sexual partner, or has had more than one sexual partner in the last year. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a>.</li><li>Pregnancy.</li><li>Gynaecological conditions such as cervical cancer — if this is suspected, refer the woman using a suspected cancer pathway referral (for an appointment within 2 weeks). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li><li>Endometrial cancer — refer women aged 55 and older using a suspected cancer pathway referral (for an appointment within 2 weeks) if they have menstrual irregularities. Refer women younger than 55 years if they have risk factors for endometrial cancer and persistent, problematic bleeding after the first 3 months of use, or if they present with a change in bleeding pattern after at least 3 months of use.<br>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li><li>Drug interactions.</li></ul></li><li><strong>Consider performing a pelvic and speculum examination:</strong><ul><li>For persistent bleeding beyond the first 3 months of use — unscheduled bleeding is common in the first 3 months of starting a new hormonal contraceptive method.</li><li>For new symptoms or a change in bleeding after at least 3 months of use.</li><li>If the woman has not participated in the National Cervical Screening programme regularly. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a>.</li><li>If requested by the woman.</li><li>If there are other symptoms such as pelvic pain, dyspareunia, or post coital bleeding. </li></ul></li><li><div>If no other underlying cause of irregular bleeding is suspected, and speculum and pelvic examination is normal, the bleeding can be assumed to be caused by the progestogen-only implant. Providing the woman has no other symptoms:</div><ul><li>Reassure the woman that unscheduled bleeding is common and that the bleeding pattern in the first 3 months is predictive of future bleeding patterns. </li><li>As a general guide:<ul><li>Around 2 in 10 women are amenorrhoeic.</li><li>Around 3 in 10 women have infrequent bleeding.</li><li>Fewer than 1 in 10 women have frequent bleeding.</li><li>Around 2 in 10 women have prolonged bleeding.</li></ul></li><li>Continue with the implant if the woman is happy to continue.</li><li>However, if bleeding is problematic, consider treating with: <ul><li>A combined oral contraceptive (30–35 micrograms of ethinylestradiol with levonorgestrel or norethisterone) either cyclically or continuously for up to 3 months, provided it is not contraindicated (off-label use). For more information, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/\">Scenario: Combined oral contraceptive pill</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li><li>Mefenamic acid 500 mg two or three times a day (or tranexamic acid 1 g four times a day) for 5 days. For more information see the section on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/prescribing-information/\">Prescribing information</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/\">Menorrhagia</a>.</li></ul></li><li>If the woman does not want treatment, or treatment fails, remove the implant and decide with the woman on another method of contraception. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul><!-- end field d7a5c6fa-35c0-4a69-a2ac-a6ce009b33a8 --><!-- end item 55c12934-eda3-4778-a6f7-a6ce009b31ea -->","subChapters":[]}]},{"id":"f263132b-6ef6-5ab5-b289-2d5041f13ec7","slug":"efficacy","fullItemName":"Efficacy","depth":3,"htmlHeader":"<!-- begin field a27a6939-fdea-42cf-aade-db871e25bad8 --><h3>How effective is the progestogen-only implant at preventing pregnancy?</h3><!-- end field a27a6939-fdea-42cf-aade-db871e25bad8 -->","summary":null,"htmlStringContent":"<!-- begin item 689a176a-fb08-48d8-acbd-5d8067f48b47 --><!-- begin field 5f38c1e2-0ab8-4700-8dfb-c81f8ba33a9f --><ul><li>For a comparison of the efficacy of progestogen-only implants with other methods of contraception, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/background-information/comparative-effectiveness-of-contraceptive-methods/\">Comparative effectiveness of contraceptive methods</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.<ul><li>When used perfectly (consistently and correctly), 0.05% of women will conceive within the first year of use due to method failure.</li></ul></li></ul><!-- end field 5f38c1e2-0ab8-4700-8dfb-c81f8ba33a9f --><!-- end item 689a176a-fb08-48d8-acbd-5d8067f48b47 -->","subChapters":[{"id":"35d036ed-c638-55aa-9f41-249eee9e2ba6","slug":"basis-for-recommendation-f81","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5323fe6c-4a5f-44cc-a1bb-df6474270d84 --><h4>Basis for recommendation</h4><!-- end field 5323fe6c-4a5f-44cc-a1bb-df6474270d84 -->","summary":null,"htmlStringContent":"<!-- begin item f81f5827-126a-45e8-96d9-f7b9eb7230bd --><!-- begin field 00f8fe7f-83bf-49c5-ada2-451121f2fda8 --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>].</p><!-- end field 00f8fe7f-83bf-49c5-ada2-451121f2fda8 --><!-- end item f81f5827-126a-45e8-96d9-f7b9eb7230bd -->","subChapters":[]}]},{"id":"4bb2726c-71ab-5be4-8e27-be6ce4340382","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3581e280-b89f-4965-9fa8-f3e690770a70 --><h3>What advice should I give regarding potential drug interactions with the progestogen-only implant?</h3><!-- end field 3581e280-b89f-4965-9fa8-f3e690770a70 -->","summary":null,"htmlStringContent":"<!-- begin item aca44991-a588-484c-99ab-9eba993a7fbc --><!-- begin field d1235a30-7b9a-4652-b3f2-3515e89efcf3 --><h4>Liver enzyme-inducing drugs</h4><ul><li>Advise the woman that liver enzyme-inducing drugs may reduce the efficacy of progestogen–only implants. Examples of liver enzyme-inducing drugs are:<ul><li>Antibiotics — rifampicin and rifabutin are very potent liver enzyme inducers.</li><li>Antiepileptic drugs such as carbamazepine, oxcarbazepine, phenytoin, barbiturates, primidone, and topiramate.<ul><li>Topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Before initiating topiramate in a woman of childbearing potential, pregnancy testing should be performed. The patient should be fully informed of the risks related to the use of topiramate during pregnancy. Ensure that women and girls of childbearing potential are advised that they should be using a highly effective method of contraception [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2017</a>]. </li></ul></li><li>Antiretrovirals such as ritonavir, ritonavir-boosted protease inhibitors, efavirenz, and nevirapine.</li><li>St John's wort — advise women using the progestogen-only implant not to take herbal products containing St John’s wort.</li></ul></li><li><strong>If a woman is on short-term treatment (2 months or less) with a liver enzyme-inducing drug</strong>:<ul><li>Advise her to change to an alternative contraceptive method unaffected by liver enzyme-inducing drugs.<ul><li>For example, remove the implant and have a one-off progestogen-only injection to cover the short-term treatment and for 28 days after.</li></ul></li><li>If this is not acceptable or possible:<ul><li>Continue the progestogen-only implant.</li><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) while taking, and for 28 days after stopping, the liver enzyme-inducing drug.</li></ul></li><li>Consider the need for emergency contraception if sexual intercourse has taken place while the efficacy of the progestogen-only implant may have been reduced, for example if the woman has already started treatment with a liver enzyme-inducing drug. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-emergency/\">Contraception - emergency</a> for more information.</li></ul></li><li><strong>If a woman is on long-term treatment (more than 2 months) with a liver enzyme-inducing drug:</strong><ul><li>Advise her to change to an alternative contraceptive method unaffected by liver enzyme-inducing drugs.</li><li>Consider the need for emergency contraception if sexual intercourse has taken place while the efficacy of the progestogen-only implant is doubtful, for example if the woman has already started treatment with a liver enzyme-inducing drug. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-emergency/\">Contraception - emergency</a> for more information.</li></ul></li></ul><h4>Griseofulvin</h4><ul><li><strong>Griseofulvin may reduce the contraceptive effect of progestogen-only implants </strong>— advise the woman to change to an alternative method of contraception unaffected by griseofulvin. </li></ul><!-- end field d1235a30-7b9a-4652-b3f2-3515e89efcf3 --><!-- end item aca44991-a588-484c-99ab-9eba993a7fbc -->","subChapters":[{"id":"688a076a-0a5a-58c6-9487-fa2ceb1d4f99","slug":"basis-for-recommendation-ebe","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 041a929e-5297-40bc-b083-8fa60321d20b --><h4>Basis for recommendation</h4><!-- end field 041a929e-5297-40bc-b083-8fa60321d20b -->","summary":null,"htmlStringContent":"<!-- begin item ebed681a-9ef1-4008-b738-a2a92a927e17 --><!-- begin field 1f5490ca-770d-464c-a716-05471cd86533 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>] and <em>Drug interactions with hormonal contraceptio</em><em>n</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2017a</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</p><!-- end field 1f5490ca-770d-464c-a716-05471cd86533 --><!-- end item ebed681a-9ef1-4008-b738-a2a92a927e17 -->","subChapters":[]}]},{"id":"52d36224-fafd-50a8-b6a6-6428050767e7","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 7108a05c-2b29-43a7-838f-6e73f9d66b0a --><h3>What follow up should I arrange for a woman using the progestogen-only implant?</h3><!-- end field 7108a05c-2b29-43a7-838f-6e73f9d66b0a -->","summary":null,"htmlStringContent":"<!-- begin item 1f82b64c-fa82-4d74-86a2-38cb77aa2da6 --><!-- begin field 4894c4fd-cfc3-4945-86d7-78d91c8669ba --><ul><li>No routine follow up is required once the progestogen-only implant has been inserted.</li><li>However, advise healthy women to return:<ul><li>When it is time to have the implant removed — after 3 years for Nexplanon®, earlier for 'heavier' women.<ul><li>The manufacturers do not provide guidance on the body mass index (BMI) above which the implant should be replaced earlier.</li></ul></li><li>At any time if:<ul><li>They cannot feel the implant.</li><li>The implant appears to have changed shape.</li><li>They notice any skin changes or pain at the site of the implant.</li><li>They become pregnant.</li></ul></li><li>If they wish to discuss:<ul><li>Changing to another method of contraception.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/#risks-adverse-effects\">Adverse effects</a> or other problems associated with the implant. </li></ul></li></ul></li></ul><!-- end field 4894c4fd-cfc3-4945-86d7-78d91c8669ba --><!-- end item 1f82b64c-fa82-4d74-86a2-38cb77aa2da6 -->","subChapters":[{"id":"647cc6dd-7742-52ec-9e1d-5d5326702e8a","slug":"duration-of-use","fullItemName":"Duration of use","depth":4,"htmlHeader":"<!-- begin field 2fb58c2c-3547-450f-bbe7-a6ce00a77d4e --><h4>How long can the progestogen-only implant be left in place?</h4><!-- end field 2fb58c2c-3547-450f-bbe7-a6ce00a77d4e -->","summary":null,"htmlStringContent":"<!-- begin item 44808399-af19-40c9-8b68-a6ce00a77b5c --><!-- begin field 072ccddf-27e5-47d9-b1c8-a6ce00a77d4e --><ul><li>Replace Nexplanon® every 3 years.</li><li>The implant can be used until the age of 55 years, or until the menopause can be confirmed. <ul><li><strong>If the woman is not amenorrhoeic,</strong> continue the progestogen-only implant over 55 years of age until she has been amenorrhoeic for 1 year. </li><li><strong>If the woman is amenorrhoeic</strong>, consider one of the following options:<ul><li>For woman over the age of 50 years, check serum follicle-stimulating hormone (FSH) levels on two occasions, with an interval of 6 weeks between tests. If both FSH levels are more than 30 IU/L, stop the progestogen-only implant after 1 year.</li><li>Continue the progestogen-only implant until the age of 55 years if required and requested.</li></ul></li></ul></li></ul><!-- end field 072ccddf-27e5-47d9-b1c8-a6ce00a77d4e --><!-- end item 44808399-af19-40c9-8b68-a6ce00a77b5c -->","subChapters":[]},{"id":"8dd82efd-8067-5747-b79a-e369a79c4897","slug":"basis-for-recommendation-c50","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 79382763-c616-411f-85da-aeb3c9381a5e --><h4>Basis for recommendation</h4><!-- end field 79382763-c616-411f-85da-aeb3c9381a5e -->","summary":null,"htmlStringContent":"<!-- begin item c50d3b0b-0c28-48b4-87ba-9e2dc44edc66 --><!-- begin field f7ab9f1a-4a38-4bf5-9851-bc9dd18a1fa8 --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only implants </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014a</a>], <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2010b</a>] and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016c</a>].</p><!-- end field f7ab9f1a-4a38-4bf5-9851-bc9dd18a1fa8 --><!-- end item c50d3b0b-0c28-48b4-87ba-9e2dc44edc66 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}